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A new member of the cystatin superfamily is introduced. Human plasma histidine-rich glycoprotein (HRG) 
was found to contain 2 cystatin-like sequences in tandem in the N-terminal region. Domain 1 (residues l- 
112) was most homologous to domain 1 of the heavy chain of human kininogen and domain 2 (residues 
113-225) was most homologous to human cystatin S as well as other cystatins and domain 3 of the heavy 
chain of kininogen, suggesting that the cystatin domains of HRG may represent a hitherto unknown binary 
form (or intermediate molecule) composed of 2 cystatin domains, and evolutionarily intermediate between 
the cystatin and the kininogen families. 
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1. INTRODUCTION 
Cysteine proteinase inhibitors (CPIs) which in- 
clude cystatins, stefins and kininogens are widely 
distributed in mammalian tissues and body fluids. 
Recently, the proteins that can be shown 
statistically to have an evolutionary relationship to 
chicken cystatin have been agreed to be called the 
cystatin superfamily [l], and a model for the 
evolution of the cystatin superfamily has also been 
proposed on the bases of sequence homology [2,3]. 
Histidine-rich glycoprotein (HRG) is a single- 
chain glycoprotein of M, 67000 present in human 
plasma. HRG is known to have many biological 
properties including interaction with heparin, 
plasminogen, thrombospondin and fibrinogen as 
well as binding of some divalent metals, heme, and 
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dyes, establishing the concept as a multifunctional 
protein [4]. 
Recently, we have reported the complete 
primary structure of HRG [5], in which we showed 
that the most part of this glycoprotein consisted of 
5 different types of internal repeats, including 
types I and II of internal repeats of 23 amino acid 
segments in the N-terminal region, and by com- 
puter search, a partial sequence (residues 30-75) in 
the N-terminal region was highly homologous to 
those of high and low molecular mass kininogens 
[S]. Here, we report the results of further study on 
the stiuctural organization of HRG that those 
types I and II of internal repeats should be in- 
volved in that of a far larger segment and show 
that the N-terminal region of HRG which consists 
of 225 amino acid residues is evolutionarily related 
to the cystatin superfamily, composed of 2 cysta- 
tin-like sequences in tandem, and accordingly we 
propose that HRG should belong to the cystatin 
superfamjy by forming a new family (the 4th 
family) between the cystatin and the kininogen 
families. 
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2. RESULTS AND DISCUSSION 
2.1. Internal repetition in the N-terminal sequence 
of HRG 
Fig.1 shows a comparison of the N-terminal 
(residues 1-112) and the contiguous (residues 
113-225) sequences of HRG. It is evident that the 
sequence of residues l-l 12 of HRG (referred to as 
HRGDl, HRG domain 1) is tandemly repeated in 
that of residues 113-225 (referred to as HRGD2, 
HRG domain 2), having 17% identity in their 
amino acid sequences (table 1) and 32% identity in 
their nucleotide sequences calculated from [5]. 
2.2. Sequence homologies to the cystatin 
superfamily 
Surprisingly, each of these repeated sequences 
Table 1 
Identity matrix of the cystatin-like domains of HRG and 
kininogen and cystatins 
HRGDl HRGD2 HKHDl HKHD2 HKHD3 
HRGDl 17 25 15 14 
HRGD2 17 14 11 19 
HKHDl 25 14 19 20 
HKHD2 15 10 19 31 
HKHD3 14 19 20 31 
HCS 15 22 15 16 23 
HCC 14 20 16 14 21 
BCPI 17 19 15 16 26 
cc 15 17 23 17 21 
The values are expressed as the percentages of residues 
identical between pairs of sequences aligned as in fig.1 
(HRGDl and HRGD2) was found to be 
homologous to the proteins of the cystatin super- 
family (fig.1). It is noteworthy that two disulfide 
bonds within cystatins and domains of kininogen 
are conserved in HRGDl and 2, with the only ex- 
ception that the first half-cystine is missing in 
HRGD2. A half-cystine is also present in HRGDl 
at the position homologous to the unique half- 
cystine in domain 1 of human kininogen heavy- 
chain (HKHDl) which connects the heavy and the 
light chains of kinin-free kininogen [6]. The 
specific site in domain 3 of human kininogen 
heavy-chain (HKHD3, shown by a solid arrow in 
fig. 1) which is selectively cleaved by trypsin [7] also 
appears to be conserved at the corresponding posi- 
tion in HRGD2 as shown by an open arrow in 
fig.1. 
Table 1 shows the identity matrix between pairs 
of sequences in the cystatin superfamily, focused 
on the comparison of the domains of HRG and 
kininogen with each other and with cystatins. The 
stefin family was not included in this table, since 
the proteins of the stefin family do not contain 
disulfide bonds and eventually HRGDl and 
HRGD2 were less homologous to this family. 
It is interesting to note that HRGDl was most 
homologous (25% identical) to HKHDl which is 
unique in the cystatin superfamily in that it does 
not possess any inhibitory activity [7], and it is also 
the case that among proteins and domains in the 
cystatin superfamily, HKHDl is structurally most 
related to HRGD 1 rather than to either HKHD2 or 
HKHD3 (table 1). HRGD2 was most homologous 
(22% identical) to human cystatin S [8] as well as 
other cystatins and HKHDS. The similarity of 
Fig. 1. Sequence homologies between HRG internal repeats and the proteins of the cystatin superfamily. HKHDl ,2 and 
3, human kininogen heavy-chain domains 1, 2 and 3 [15]; HRGDl and 2, HRG domains 1 and 2 [5]; HCS, cystatin 
S from human saliva [8]; HCC, cystatin C (r-trace) from human plasma [la]; BCPI, cysteine proteinase inhibitor from 
bovine colostrum [17]; CC, cystatin from chicken egg white [l&19]; HCA, cystatin A (stefin) from human granulocytes 
[20]; HCB, cystatin B from human liver [21]; RLTPI, thiol proteinase inhibitor from rat liver [22]; RETPI, thiol 
proteinase inhibitor from rat epidermis [23]. The proteins of the cystatin superfamily are grouped into kininogen 
(HKHDl, 2 and 3), cystatins (HCS, HCC, BCPI and CC) and stefins (HCA, HCB, RLTPI and RETPI). The residue 
number at the top line of sequence alignment is that of HRG starting with the N-terminal valine. Residues identical 
between HRG internal repeats are shaded, and sequence identities among the HRG internal repeats and at least one 
of the other inhibitors are boxed. The 3 internal repeats (1-113, 114-235 and 236-357) in the heavy-chain of kininogen 
as proposed by [2,7] are shown according to the gene structural organization, and triangles (v) indicate the position 
of introns in kininogen gene [14]. The disulfide bonds in kininogen domains [6] and cystatins [24] are shown by I 
and the potential reactive sites of CPIs are marked by the bold solid bar. The peptide bond in kininogen which is 
specifically cleaved by trypsin [8] is shown by a solid arrow, and a corresponding potential cleavage site in HRG is shown 
by an open arrow. 
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hydropathy profiles of HRGDl and 2 [5] and those 
of cystatins and kininogen domains [2] further 
supports their close relationships (not shown). 
The potential reactive-site sequence of CPIs pro- 
posed as QVVAG is partly conserved in HRGDl 
and 2. Q (glutaminyl residue), the only amino acid 
residue that is common among CPIs and not com- 
mon to non-inhibitor members (HKHDl , 
HRGDl, and HRGD2) of the cystatin superfami- 
ly, may be the most critical residue for the in- 
hibitory activity. 
2.3. Evolutionary and functional aspects of the 
N-terminal domains of HRG 
The cystatin superfamily has recently been 
classified into 3 families [2]. One is the cystatin 
family involving cystatins of various origins, a 
second is the kininogen family composed of the 
heavy chains of high-& low-M, and related 
kininogens, and a third is the stefin family com- 
prising low-M,, non-disulfided CPIs. In the 
kininogen family, 3 cystatin-like domains, only 2 
of which show inhibitory activities [7], consist in a 
single polypeptide, representing a multi-headed in- 
hibitor [9] in the cystatin superfamily. 
Present results that HRG contains 2 cystatin-like 
domains in the N-terminal region of the polypep- 
tide, and that these domains 1 and 2 are extensively 
homologous to domains 1 and 3, respectively, of 
the heavy chain of kininogen may lead us to in- 
clude HRG in the kininogen family. However, we 
propose to develop a new family, since kininogen 
contains 3 cystatin-like sequences, while HRG con- 
tains 2 cystatin-like sequences. Thus, HRG may 
represent a hitherto unknown binary form (or in- 
termediate molecule) composed of 2 cystatin units 
as predicted in [2,3]. HRG, therefore, may in- 
termediate between the cystatin and the kininogen 
families in the genealogy of mammalian CPIs as 
proposed in [2,3]. 
Ovalbumin [lo], angiotensinogen [111, barley 
endosperm protein Z [12] and thyroxine-binding 
globulin [13] are known as non-inhibitor members 
in the antithrombin III superfamily (also referred 
to as the serpin superfamily). In spite of many 
functional properties of HRG [4], no cystatin-like 
activity has ever been reported for HRG. 
Therefore, HRG may be the first non-inhibitor 
member of the cystatin superfamily. In our 
preliminary experiment, HRG showed some in- 
20 
hibitory capability when assayed with papain. 
However, it is possible that this observation is due 
not to the interaction between the active site of 
protease and the reactive site of inhibitor, but to an 
allosteric effect or some side effect, because the in- 
hibition was very weak and non-stoichiometric. 
The property of HRG as a cysteine proteinase in- 
hibitor is now under investigation. 
Each cystatin domain of kininogen has been 
shown to be composed of 3 exons separated by 2 
introns in kininogen gene [14] (fig.1). It is in- 
teresting and important in evolutionary aspects to 
know whether the cystatin domains of HRG con- 
sist of the same or similar intron-exon organization 
as those of kininogen. The characterization of the 
HRG gene also is in progress. 
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